Qualitative Survey-Based Evaluation of Operability and Convenience for the Etanercept Biosimilar YLB113 in a Unique Injection Pen in Patients with Rheumatoid Arthritis

Category: Original Research
Author(s): , , ,
Visits: 102 total, 3 today
Keywords: etanercept, injection pen, needle fear, rheumatoid arthritis, usability, YLB113

Objective: Needle fear is common among patients with rheumatoid arthritis (RA) who require subcutaneous (SC) injections. The convenience, usability, and safety of the etanercept biosimilar YLB113 in an injection pen were evaluated among patients who switched from syringe injection.
Methods: Patients with RA who had completed the phase 3 clinical study of YLB113 in a prefilled syringe (YLB113-002) were enrolled (n = 35) and received once-weekly SC injections with the injection pen (YLB113 50 mg) for 8 weeks. After 8 weeks, patients completed a qualitative survey evaluating the form and design of the pen, its operability, and patient preference for pen or syringe. Adverse events were evaluated throughout the study.
Results: Most patients reported the pen was “very easy to grasp” or “easy to grasp”. The pen was also reported to be easy to operate. The click signalling the start and end of the injection could be heard very well or well. Similarly, the injection solution check window could be seen by most patients. About three-quarters of respondents preferred the pen over a syringe. The pen was considered easier to use for the following reasons: the body is easy to grasp; the procedure is easy to understand; and the procedure can be performed without anxiety, fear, or tenseness.
Conclusion: YLB113 50 mg delivered by injection pen is easy to use, convenient, and safe, and is preferred over a syringe by most patients with RA in the study.

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply